Session » (1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1436

Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients

10:30AM-12:30PM: Abstract Number: 1449

Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1439

Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients

10:30AM-12:30PM: Abstract Number: 1451

Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1437

Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications

10:30AM-12:30PM: Abstract Number: 1452

Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry

10:30AM-12:30PM: Abstract Number: 1458

Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1440

Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1461

Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1460

Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study

10:30AM-12:30PM: Abstract Number: 1463

Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study

10:30AM-12:30PM: Abstract Number: 1441

Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study

10:30AM-12:30PM: Abstract Number: 1462

Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study

10:30AM-12:30PM: Abstract Number: 1459

Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials

10:30AM-12:30PM: Abstract Number: 1466

Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension

10:30AM-12:30PM: Abstract Number: 1435

Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study

10:30AM-12:30PM: Abstract Number: 1464

Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study

10:30AM-12:30PM: Abstract Number: 1448

Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study

10:30AM-12:30PM: Abstract Number: 1447

Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies

10:30AM-12:30PM: Abstract Number: 1443

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study

10:30AM-12:30PM: Abstract Number: 1454

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1456

Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study

10:30AM-12:30PM: Abstract Number: 1442

Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 1445

Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study

10:30AM-12:30PM: Abstract Number: 1446

Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action

10:30AM-12:30PM: Abstract Number: 1444

Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis

10:30AM-12:30PM: Abstract Number: 1453

Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors

10:30AM-12:30PM: Abstract Number: 1457

Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study

10:30AM-12:30PM: Abstract Number: 1434

Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort

10:30AM-12:30PM: Abstract Number: 1438

Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension

10:30AM-12:30PM: Abstract Number: 1455

Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design

10:30AM-12:30PM: Abstract Number: 1465

Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials

10:30AM-12:30PM: Abstract Number: 1450

The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].